Back to Quality Research
AFYAAfya Ltd
Consumer Staples · Household Products · Small
$15.09+1.21%
As of 23 Oct 2026Mkt cap $1.3B
Stage 13
BUY
Fundamentals
57.0/75
Technical
9.8/15
Independent
66.9/90
GCAE viewstrong Fundamental /75 and actionable Technical v2 timing align · Rotation is a supportive tailwind but contributes no score points
Price
- 1M
- +9.9%
- 3M
- +6.3%
- 6M
- +8.0%
- 1Y
- +1.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 16.1%
- Operating margin
- 30.6%
- FCF margin
- 36.9%
- Current ratio
- 2.2x
Growth
- Revenue growth
- +7.4%Latest FY YoY
- Revenue CAGR
- +20.0%
- EPS CAGR
- +35.2%
- FCF CAGR
- +27.1%
Capital
- Share-count trend
- +0.4%3Y annualised
- Net debt
- $362M1.3x OCF
Annual trend
- CAGR 2021–2025
- +20.0%
- Latest · 2025
- $1B
- YoY
- +7.4%
GCAE Research
- Quality Research
- MIXED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fresh 24 October review found no material company-specific evidence sufficient to change the approved qualitative verdict; the stated watch items remain unresolved.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Afya programs under active ENAMED measures
- admissions/seat authorizations at affected campuses
- next ENAMED remediation results.
More details & evidence
Production decision
- Stage 13
- BUY
- Technical state
- early-recovery
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded